Moreover, the p110α-selective inhibitor alpelisib combined with a CDK4/6 inhibitor was revealed to significantly improve tumor-infiltrating CD4 + and CD8 + T cell activity and reduce the abundance of MDSCs in TNBC mouse models [52].These findings strongly indicate a reshaping effect on the antitumor TIM induced by selective p110α inhibitor, as well as their potential, together with ICBs, in cancer therapy. The gene discussed is CD4; the disease is neoplasm.